Abstract
The prostaglandins (PGs) are a group of lipids synthesized from arachidonic acid via the cyclooxygenase pathway; other cyclooxygenase products, including thromboxane and prostacyclin, as well as lipoxygenase- dependent products of arachidonate, which include the leukotrienes and hydroxyeicosatetraenoic acids, are collectively referred to as eicosanoids (reviewed in 1). While interest in all eicosanoids has increased vis a vis cancer (reviewed in 2), this review will focus on the primary prostaglandins, i.e., 20-carbon, unsaturated lipids, designated by letters, e.g., PGE2, PGF2α , PGD2, etc. PGE2 has been studied most extensively.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Nelson, N.A., Kelly, R.C., Jr., and Johnson, R.A. Prostaglandins and the arachidonic acid cascade. Chem. Eng. News 60: 30–44, 1982.
Honn, K.V., Bockman, R.S and Marnett, L.J. Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins 21: 833–864, 1981.
Carter, C.A., Milholland, R.J., Shea, W. and Ip, M.M. Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-DMBA- induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res. 43: 3559–3562, 1983.
Abraham, S., Faulkin, L.J., Hillyard, L.A. and Mitchell, D.J. Effect of dietary fat on tumorigenesis in the mouse mammary gland. J. Natl. Cancer Inst. 72: 1421–1429, 1984.
McCormick, D.L., Madigan, M.J. and Moon, R.C. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res. 45: 1803–1808, 1985.
Levine, L. Prostaglandin production by mouse fibrosarcoma cells in culture: inhibition by indomethacin and aspirin. Biochem. Biophys. Res. Commun. 47: 888–896, 1972.
Strausser, H.R. and Humes, J.L. Prostaglandin synthesis inhibition: effect on bone changes and sarcoma tumor induction in Balb/c mice. Int. J. Cancer 15: 724–730, 1975.
Galasko, C.S.B., Rawlins, R. and Bennett, A. Timing of indomethacin in the control of prostaglandins, osteoclasts and bone destruction produced by VX2 carcinoma in rabbits. Br. J. Cancer 40: 360–364, 1979.
Young, M.R. and Knies, S. Prostaglandin E production by Lewis lung carcinoma: mechanism for tumor establishmentin vivo. J. Natl. Cancer Inst. 72: 919–922, 1984.
Trevisani, A., Ferretti, E., Capuzzo, A. and Tomasi, V. Elevated levels of prostaglandin E2 in Yoshida hepatoma and the inhibition of tumor growth by non-steroidal anti-inflammatory drugs. Br. J. Cancer 41: 341–347, 1980.
Favalli, C., Garaci, E., Etheredge, E., Santoro, M.G. and Jaffe, B.M. Influence of PGE on the immune response in melanoma bearing mice. J. Immunol. 125: 897–902, 1980.
Tan, W.C., Privett, O.S. and Goldyne, M.E. Studies of prostaglandins in rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene. Cancer Res. 34: 3229–3231, 1974.
Karmali, R., Thaler, H.T. and Cohen, L. Prostaglandin concentrations and prostaglandin synthetase activity in N-nitrosomethylurea- induced rat mammary adenocarcinoma. Eur. J. Cancer Clin. Oncol. 19: 817–823, 1983.
Bennett, A., Carroll, M.A., Melhuish, P.B. and Stamford, I.F. Treatment of mouse carcinomain vivowith a prostaglandin E2 analogue and indomethacin. Br. J. Cancer 52: 245–249, 1985.
Fulton, A.M. and Heppner, G.H. Relationships of prostaglandin E and natural killer sensitivity to metastatic potential in murine mammary adenocarcinomas. Cancer Res. 45: 4779–4784, 1985.
Fulton, A.M. Effects of indomethacin on the growth of cultured mammary tumors. Int. J. Cancer 33: 375–379, 1984.
Mahoney, K.H., Fulton, A.M. and Heppner, G.H. Tumor-associated macrophages of mouse mammary tumors. II. Differential distribution of macrophages from metastatic and nonmetastatic tumors. J. Immunol. 131: 2079–2085, 1983.
Powles, T.J., Clark, S.A., Easty, D.M., Easty, G.C. and Neville, A.M. The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcemia in rats with Walker tumor and its possible application to human breast cancer. Br. J. Cancer 28: 316–321, 1973.
Bennett, A., Houghton, J., Leaper, D.J. and Stamford, I.F. Cancer growth, response to treatment and survival time in mice: beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen. Prostaglandins 2: 179–191, 1979.
Humes, J.R. and Strausser, H.R. Prostaglandins and cyclic nucleotides in Moloney sarcoma tumors. Prostaglandins 5: 183–196, 1974.
Lynch, N.R. and Salomon, J.-C. Tumor growth inhibition and potentiation of immumotherapy by indomethacin in mice. J. Natl. Cancer Inst. 62: 117–-121, 1979.
Plescia, O.J., Smith, A.H. and Grinwich, K. Subversion of immune system by tumor cells and role of prostaglandins. Proc. Nat. Acad. Sci. 72: 1848–1851, 1975.
Hial, V., Horakova, Z., Shaff, R.E. and Beavan, M.A. Alteration of tumor growth by aspirin and indomethacin: studies with two transplantable tumors in mouse. Eur. J. Pharmacol. 37: 367–376, 1976.
Voelkel, E.F., Tashjian, A.H., Frankin, R., Wasserman, E. and Levine, L. Hypercalcemia and tumor-prostaglandins: the VX2 carcinoma model in the rabbit. Metabolism 24: 973–986, 1975.
Tashjian, A.H., Jr. Role of prostaglandins in the production of hypercalcemia by tumors. Cancer Res. 38: 4138–4141, 1978.
Seyberth, H.W., Bonsch, G., Muller, H., Minne, H.W., Erlenmaier, T., Strein, K., Imbeck, H. and Mrongovius, R. Prostaglandin E production and hypercalcemia in rats bearing the Walker carcinosarcoma. Br. J. Cancer 42: 455–461, 1980.
Santoro, M.G., Philpott, G.W. and Jaffe, B.M. Inhibition of tumor growthin vivoandin vitroby prostaglandin E. Nature 263: 777–779, 1976.
Favalli, C., Garaci, E., Santoro, M.G., Santucci, L. and Jaffe, B.M. The effect of PGA1 on the immune response in B-16 melanoma-bearing mice. Prostaglandins 19: 587–594, 1980.
Kobayashi, H., Ojima, M., and Satoh, H. Effects of 6-keto-prostaglandin E1 on ascitic hepatoma-130in vivo: comparison with chemotherapeutic agents. Prostaglandins 29: 255–268, 1985.
Higashida, H., Kano-Tanaka, K., Natsuume-Sakai, S., Sudo, K., Fukami, H., Nakagawa, Y. and Miki, N. Cytotoxic action of prostaglandin D2 on mouse neuroblastoma cells. Int. J. Cancer 31: 797–802, 1983.
Hillyard, L.A. and Abraham, S. Effect of dietary polyunsaturated fatty acids on growth of mammary adenocarcinomas in mice and rats. Cancer Res. 39: 4430–4437, 1979.
Fulton, A.M.In vivoeffects of indomethacin on the growth of murine mammary tumors. Cancer Res. 44: 2416–2420, 1984.
Fulton, A.M. and Levy, J.G. Inhibition of murine tumor growth and prostaglandin synthesis by indomethacin. Int. J. Cancer 26: 669–673, 1980.
Jubiz, W., Frailey, J. and Smith, J.B. Inhibitory effect of PGF2αon the growth of a hormone-dependent rat mammary tumor. Cancer Res. 39: 998–1000, 1979.
Jacobson, H.I. Oncolytic action of prostaglandins. Cancer Chemotherap. Rep. 58 (part 1): 503–511, 1974.
Foecking, M.K., Kibbey, W.E., Abou-Issa, H., Matthews, R.H. and Minton, J.P. Hormone dependence of 7,12-dimethylbenz(a)anthracene-induced mammary tumor growth: correlation with prostaglandin E2 content. J. Natl. Cancer Inst. 69: 443–446, 1982.
Foecking, M.K., Abou-Issa, H., Webb, T.E. and Minton, J.P. Concurrent changes in growth related biochemical parameters during regression of hormone-dependent rat mammary tumors. J. Natl. Cancer Inst. 71: 773–778, 1983.
Liu, S.C. and Knazek, R.A. Prostaglandin synthesis and binding is increased in regressing NMU mammary carcinoma. Prostagl. Leuk. Med. 8: 191–198, 1982.
Karmali, R.A. Growth inhibition and prostaglandin metabolism in the R3230AC mammary adenocarcinoma by reduced glutathione. Cancer Biochem. Biophys. 7: 147–154, 1984.
Karmali, R.A., Horrobin, D.F., Menezes, J. and Patel, P. The relationship between concentrations of prostaglandins A1, E2, and E2 α and rates of cell proliferation. Pharmacol. Res. Commun. 11: 69–75, 1979.
Tisdale, M.J., Gibbs, J. and Dobrzanski, R.J. Effect of chlorambucil and indomethacin on growth and prostaglandin levels in sensitive and resistant Walker carcinoma. Chem. Biol. Interactions 39: 221–230, 1982.
Yoneda, T., Kitamura, M., Ogawa, T., Aya, S.-I. and Sakuda, M. Control of VX2 carcinoma cell growth in culture by calcium, calmodulin and prostaglandins. Cancer Res. 45: 398–405, 1985.
Thomas, D.R., Philpott, G.W. and Jaffe, B.M. The relationship between concentration of prostaglandin E and rates of cell replication. Expt. Cell Res. 84: 40–46, 1974.
Reichel, P., Cohen, L.A., Karmali, R., Schuessler, G.J. and Rose, D.P. The effects of flurbiprofen on growth, prostaglandin production, and lactogenic-hormone binding capacity of cultured human breast and prostate carcinoma cells. Proc. AACR 26: 195, 1985.
Bregman, M.D., Sander, D. and Meyskens, F.L., Jr. Prostaglandin A1 and E1 inhibit the plating efficiency and proliferation of murine melanoma cells (Cloudman S-91) in soft agar. Biochem. Biophys. Res. Comm. 104: 1080–1086, 1982.
Kuehl, F.A., Jr., Humes, J.L., Firillo, V.J. and Ham, E.A. Cyclic AMP and prostaglandins in hormone action.In: P. Greengard, R. Paoletti, G.A. Robinson (eds.), Advances in cyclic nucleotide research. Vol. 1, pp 498–502, New York, Raven Press, 1972.
Honn, K.V., Romine, M. and Skoff, A. Prostaglandin analogs as inhibitors of tumor cell DNA synthesis. Proc. Soc. Expt. Biol. Med. 166: 562–567, 1981.
Honn, K.V. and Marnett, L.J. Requirement of a reactiveα,β-unsaturated carbonyl for inhibition of tumor growth and induction of differentiation by “A” series prostaglandins. Biochem. Biophys. Res. Comm. 129: 34–40, 1985.
Otto, A.M., Nilsen-Hamilton, M., Boss, B.D., Ulrich, M.-O. and Jimenez de Asua, L. Prostaglandins E1 and E2 interact with prostaglandin F2 αto regulate initiation of DNA replication and cell division in Swiss 3T3 cells. Proc. Natl. Acad. Sci. 79: 4992–4996, 1982.
Kawamura, M. and Koshihara, Y. Prostaglandin D2 strongly inhibits growth of murine mastocytoma cells. Prostagl. Leuk. Med. 12: 85–93, 1983.
Fukushima, M., Kato, T., Ueda, R., Ota, K., Narumiya, S. and Hayaishi, 0. Prostaglandin D2, a potential antineoplastic agent. Biochem. Biophys. Res. Commun. 105: 956–964, 1982.
Mahmud, I., Smith, D.L., Whyte, M.A., Nelson, J.T., Cho, D., Tokes, L.G., Alvarez, R. and Willis, A.L. On the differentiation and biological properties of prostaglandin J2. Prostagl. Leuk. Med. 16: 131–146, 1984.
Knazek, R.A. and Liu, S.C. Effects of dietary essential fatty acids on murine mammary gland development. Cancer Res. 41: 3750–3751, 1981.
Rudland, P.S., Twiston-Davies, A.C. and Tsao, S.-W. Rat mammary preadipocytes in culture produce a trophic agent for mammary epithelia-prostaglandin E2. J. Cell. Physiol. 120: 364–376, 1984.
Bennett, A., Charlier, E.M., McDonald, A.M., Simpson, J.S., Stamford, I. F. and Zebro, T. Prostaglandins and Breast Cancer. Lancet 2: 624–626, 1977.
Bennett, A., Berstock, D.A., Raja, B. and Stamford, I.F. Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers. Br. J. Pharmacol. 66: 451, 1979.
Powles, T.J., Dowsett, M., Easty, D.M., Easty, G.C. and Neville, A.M. Breast cancer osteolysis, bone metastases and anti-osteolytic effect of aspirin. Lancet 1: 608–610, 1976.
Dady, P.J., Powles, T.J., Dowsett, M., Easty, G., Williams, J. and Neville, A.M.In vitroosteolytic activity of human breast carcinoma tissue and prognosis. Br. J. Cancer 43: 222–225, 1981.
Rolland, P.H., Martin, P.M., Jacquemier, J., Rolland, A.M. and Toga, M. Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J. Natl. Cancer Inst. 64: 1061–1070, 1980.
Malachi, T., Chaimoff, Ch., Feller, N., and Halbrecht, I. PGE2 and cyclic AMP in tumor and plasma of breast cancer patients. J. Cancer Res. Clin. Oncol. 102: 71–79, 1981.
Karmali, R.A., Walt, S., Thaler, H.T. and Lefevre, F. Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br. J. Cancer 48: 689–696, 1983.
Hortobagyi, G.N., Schultz, P., Cailleau, R., Samaan, N. and Blumenschein, G.In vitroprostaglandin production by metastatic breast cancer. In: Powles, T.W., Bockman, R.F., Honn, K.V. (eds.) Prostaglandins and Cancer: First International Conference, pp 567–572, New York, Alan R. Liss, Inc., 1982.
Gunasegaram, R., Loganath, A., Peh, K.L., Chiang, S.C. and Ratnam, S.S. Indentification of prostaglandins in infiltrating duct carcinoma of the human breast. IRCS Med.Sci. 8: 747–748, 1981.
Bishop, H.M., Haynes, J., Evans, D.F., Elston, C.W., Johnson, J. and Blarney, R.W. Radioimmunoassay of prostaglandin E2 in primary breast cancer and its relationship to histological grade. Clin. Oncol. 6: 380–381, 1980.
Kibbey, W.E., Bronn, D.G. and Minton, J.P. Prostaglandin synthetase and prostaglandin E2 levels in human breast carcinoma. Prostagl. Medicine 2: 133–139, 1979.
Watson, D.M.A., Kelly, R.W., Hawkins, R.A. and Miller, W.R. Prostaglandins in human mammary cancer. Br. J. Cancer 49: 459–464, 1984.
Vergote, I.B., Laekeman, G.M., Keersmaekers, G.H., Uyttenbroeck, F.L., Vanderheyden, J.S., Albertyn, G.P., Haensch, C.F., DeRoy, G.J. and Herman, A.G. Prostaglandin F2 αin benign and malignant breast tumors. Br. J. Cancer 51: 827–836, 1985.
Nigam, S., Becker, R., Rosendahl, U., Hammestein, J., Benedetto, C., Barbero, M. and Slater, T.F. The concentrations of 6-keto-PGF1 α and TXB2 in plasma samples from patients with benign and malignant tumors of the breast. Prostaglandins 29: 513–528, 1985.
Aitokallio-Talberg, A., Karkkainen, J., Pantzar, P., Wahlstrom, T. and Ylikorkala, O. Prostacyclin and thromboxane in breast cancer: relationship between steriod receptor status and medroxyprogesterone acetate. Br. J. Cancer 51: 671–674, 1985.
Fulton, A., Roi, L., Howard, L., Russo, J., Brooks, S. and Brennan, M.J. Tumor associated prostaglandins in patients with primary breast cancer: relationship to clinical parameters. Breast Cancer Res. Treatment 2: 331–337, 1982.
Fulton, A., Roi, L., Howard, L., Russo, J., Brooks, S. and Brennan, M.J. Tumor associated prostaglandins in patients with primary breast cancer: relationship to clinical parameters. Breast Cancer Res. Treatment 2: 331–337, 1982.
Fidler, I.J. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 38: 3651–3660, 1978.
Gasic, G.J., Gasic, T.B., Galanti, N., Johnson, T. and Murphy, S. Platelet-tumor cell interactions in mice. The role of platelets in the spread of malignant disease. Int. J. Cancer 11: 704–718, 1973.
Ambrus, C.M., Ambrus, J.L., Gastpar, H. and Sparrento, P. Effect of platelet aggregation inhibitors on metastatic distribution of neoplastic cells. Proc. AACR 22: 266, 1981.
Maat, B. and Hilgard, P. Anticoagulants and experimental metastases — evaluation of antimetastatic effects in different model systems. J. Cancer Res. Clin. Oncol. 101: 275–283, 1981.
Zacharski, L.R., Henderson, W.G., Rickles, F.R., Forman, W.B., Cornell, C.J., Forcier, R.J., Harrower, H.W. and Johnson, R.O. Rationale and experimental design for the VA cooperative study of anticoagulation (Warfarin) in the treatment of cancer. Cancer 44: 732–741, 1979.
Pearlstein, E., Salk, P.L., Yogeeswaran, G. and Karpatkin, S. Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts, and cell surface sialyation in 10 metastatic variants derivatives of rat renal sarcoma cell line. Proc. Natl. Acad. Sci. 77: 4336–4339, 1980.
Honn, K.V., Cicone, B. and Skoff, A. Prostacyclin: A potent antimetastatic agent. Science 212: 1270–1272, 1981.
Mehta, P., Ostrowski, N. and Brigmon, L. Decreased stabilization of prostacyclin activity in patients with bone tumors. Cancer Res. 44: 3132–3134, 1984.
Fitzpatrick, F.A. and Stringfellow, D.A. Prostaglandin D2 formation by malignant melanoma cells correlates inversely with cellular metastatic potential. Proc. Natl. Acad. Sci. 76: 1765–1769, 1979.
Stringfellow, D.A. and Fitzpatrick, F.A. Prostaglandin D2 controls pulmonary metastasis of malignant melanoma cells. Nature 282: 76–78, 1979.
Honn, K.V., Busse, W.D. and Sloane, B.F. Prostacyclin and thromboxanes: Implications for their role in tumor cell metastasis. Biochem. Pharmacol. 32: 1–11, 1983.
Maniglia, C.A., Loulakis, P. and Sartorelli, A.C. Nafazatrom inhibition of B16 amelanotic tumor cell spontaneous metastasis and endothelial extra-cellular matrix degradation. Proc. AACR 26: 59, 1985.
Karpatkin, S., Ambrogio, C. and Pearlstein, E. Lack of effect ofin vivo prostacyclin on the development of pulmonary metastasis in mice following intravenous injection of CT26 colon carcinoma, Lewis lung carcinoma, or B16 amelanotic melanoma cells. Cancer Res. 44: 3880–3883, 1984.
Haas, J.S., Corbett, T.H., and Haas, C.D. Nafazatrom: Lack of antimetastatic effect. Proc. AACR 26: 51, 1985.
Mahan, M., Meunier, J., Newby, M., and Young, M.R. Prostaglandin E2 production by EL4 leukemia cells from C57 Bl/6 mice: mechanism for tumor dissemination. J. Natl. Cancer Inst. 74: 191–195, 1985.
Young, M.R., Newby, M., and Meunier, J. Relationships between morphology, dissemination, migration and prostaglandin E2 secretion by cloned 2 variants of Lewis lung carcinoma. Cancer Res. 45: 3918–3923, 1985.
Webb, D.R. and Osheroff, P.L. Antigen stimulation of prostaglandin synthesis and control of immune responses. Proc. Natl. Acad. Sci., 73: 1300–1309, 1976.
Goodwin, J.S., Bankhurst, A.D., and Messner, R.P. Suppression of human T-cell mitogenesis by prostaglandin. J. Exp. Med., 146: 1719–1734, 1977.
Goodwin, J.S. and Ceuppens, J. Regulation of the immune response by prostaglandins. J. Clin. Immunol. 3: 295–315, 1983.
Schultz, R.M., Pavlidis, N.A., Stylos, W.A., and Chirigos, M.A. Regulation of macrophage tumoricidal function: A role for prostaglandins of the E series. Science 202: 320–321, 1978.
Brunda, M.J., Herberman, R.B., and Holden, H.T. Inhibition of murine natural killer cell activity by prostaglandins. J. Immunol. 124: 2682–2688, 1980.
Droller, M.J., Schneider, M.U., and Perlmann, P. A possible role of prostaglandins in the inhibition of natural and antibody dependent cell-mediated cytotoxicity against tumor cells. Cell. Immunol. 39: 165–177, 1978.
Russell, S.W. and Pace, J.L. Both the kind and magnitude of stimulus are important in overcoming the negative regulation of macrophage activation by PGE2. J. Leuk. Biol. 35: 291–301, 1984.
Snider, M.E., Fertel, R.H., and Zwilling, B.S. Prostaglandin regulation of macrophage function: effect of endogenous and exogenous prostaglandins. Cell. Immunol. 74: 234–242, 1982.
Kendall, R. and Targan, S. The dual effect of prostaglandin and ethanol on the natural killer cytolytic process. J. Immunol, 125: 2770–2777, 1980.
Favalli, C., Leport, P., Jaffe, B.M., Santoro, M.G., Simmet, T., Del Gobbo, V., and Garaci, E. The differential effects of PGE on the immune response in normal and immunosuppressed mice. Cell. Immunol., 72: 351–359, 1982.
Pelus, L.M. and Strausser, H.R. Indomethacin enhancement of spleen cell responsiveness to mitogen stimulation in tumorous mice. Int, J. Cancer 18: 653–660, 1976.
Lynch, N.R., Castes, M., Astoin, M., and Salomon, J,-C. Mechanism of inhibition of tumor growth by aspirin and indomethacin, Br, J. Cancer 38: 503–512, 1978.
Droller, M.J. and Gomolka, D. Interferon induction and prostaglandin synthetase inhibition in thein vitroandin vivomanipulation of immune response expression in an animal model of bladder cancer, Cell. Immunol. 72: 1–13, 1982.
Goodwin, J.S., Messner, R.P., Bankhurst, A.D., Peake, G.T., Saiki, J.H. and Williams, R.J., Jr. Prostaglandin-producing suppressor cells in Hodgkin’s disease. N. Engl. J. Med. 197: 263–269, 1977.
Balch, C.M., Dougherty, P.A., Cloud, G.A., and Tilden, A.B. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery, 95: 71–76, 1984.
Pelus, L.M. and Bockman, R.S. Increased prostaglandin synthesis by macrophages from tumor-bearing mice. J. Immunol. 123: 2118–2125, 1979.
Cameron, D.J. and O’Brien, P. Relationship of the suppression of macrophage mediated tumor cytotoxicity in conjunction with secretion of prostaglandin from the macrophages of breast cancer patients. Int. J. Immunopharmacol. 4: 445–450, 1982.
Tilden, A.B. and Balch, C.M. Immune modulatory effects of indometha- cin in melanoma patients are not related to prostaglandin E2- mediated suppression. Surgery 92: 528–532, 1982.
Hanna, N. and Fidler, I.J. Role of natural killer cells in the destruction of circulating tumor emboli. J. Natl. Cancer Inst. 65: 801–809, 1980.
Gorelik, E., Wiltrout, R.H., Okumura, K., Habu, S., and Herberman, R. Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int. J. Cancer 30: 107–112, 1982.
Eccles, S.A. and Alexander, P. Macrophage content of tumors in relation to metastatic spread and host immune reactions. Nature 250: 667–669, 1974.
Loveless, S.E. and Heppner, G.H. Tumor-associated macrophages of mouse mammary tumors. I. Differential cytotoxicity of macrophages from metastatic and nonmetastatic tumors. J. Immunol. 131: 2074–2078, 1983.
Yamashina, K., Fulton, A., and Heppner. G. Differential sensitivity of metastatic versus nonmetastatic mammary tumor cells to macrophage-mediated cytostasis. J. Natl. Cancer Inst., 75: 765–770, 1985.
Fulton, A.M., Hanchin, C.M., and Butler, W.B. Identification of prostaglandin E2 receptors in murine mammary tumor cells. (Submitted for publication).
Bonne, C., Martin, B., Watada, M., and Regnault, F. The antagonism of prostaglandins I2, E1 and D2 by prostaglandin E2 in human platelets. Thrombosis Res. 21: 13–22, 1981.
Goodwin, J.S., Wiik, A., Lewis, M., Bankhurst, A.D., and Williams, R.C., Jr. High affinity binding sites for prostaglandin E on human lymphocytes. Cell Immunol. 43: 150–159, 1979.
Fernandez-Botran and Suzuki, T. Prostaglandin sensitive adenyl cyclase of a murine macrophage-like cell line (P388D1): II. Isolation and partial characterization of PGE2 binding proteins. J. Immunol. 133: 2662–2667, 1984.
Karaplis, A.C. and Powell, W.S. Specific binding of prostaglandins E1 and E2 to adrenal medulla. J. Biol. Chem. 256: 2414–2419, 1981.
Brunton, L.L., Wiklund, R.A., Van Arsdale, P.M., and Gilman, A.G. Binding of 3H-prostaglandin E2 to putative receptors linked to adenylate cyclase of cultured cell clones. J. Biol. Chem. 251: 3037–3044, 1976.
Abou-Issa, H. and Minton, J.P. Loss of prostaglandin E receptors during progression of rat mammary tumors from hormonal dependence to autonomy. J. Natl. Cancer Inst. 76: 101–106, 1986.
Seyberth, H.W., Segre, G.V., Morgan, J.L., Sweetman, B.J., Potts, J.T, Jr., and Oates, J.A. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. New Eng. J. Med. 293: 1278–1283, 1975.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Plenum Press, New York
About this chapter
Cite this chapter
Fulton, A.M. (1987). Prostaglandins in Breast Cancer. In: Medina, D., Kidwell, W., Heppner, G., Anderson, E. (eds) Cellular and Molecular Biology of Mammary Cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0943-7_15
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0943-7_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-42761-9
Online ISBN: 978-1-4613-0943-7
eBook Packages: Springer Book Archive